A Phase I Study Evaluating Safety and Efficacy of Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma
Latest Information Update: 21 May 2024
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Acronyms HIPANIV
- 01 Apr 2021 New trial record